Trial Profile
BioNIR Ridaforolimus Eluting Coronary Stent System (BioNIR) In Coronary Stenosis Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ridaforolimus (Primary)
- Indications Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms BIONICS
- Sponsors Medinol
- 25 Mar 2018 Status changed from recruiting to completed.
- 30 Oct 2016 Status changed from not yet recruiting to recruiting.
- 19 Jul 2016 New trial record